L. Burns

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Lindsay H. Burns, L. H. Burns, Lindsay H Burns, L H Burns, L. H Burns, Lindsay Burns
Publication record
35 papers · 2,191 citations · H-index 22

PAPERS

Simufilam suppresses overactive mTOR and restores its sensitivity to insulin in Alzheimer’s disease patient lymphocytes
20239 citationsauthor #8
Targeting α7 nicotinic acetylcholine receptors and their protein interactions in Alzheimer's disease drug development
202327 citationsauthor #1
Encouraging interim results at 9 months from an open‐label study of simufilam in patients with Alzheimer’s disease
20212 citationsauthor #1
Effects of simufilam on cerebrospinal fluid biomarkers in Alzheimer’s disease: A randomized clinical trial
20210 citationsauthor #16
Editorial note: "Ultra-low-dose naloxone suppresses opioid tolerance, dependence, associated changes in mu opioid receptor-G protein coupling, Gβγ signalling" [Neuroscience 135(1)(2005)247-261].
20211 citationsauthor #4
SavaDx, a novel plasma biomarker to detect Alzheimer’s disease, confirms mechanism of action of simufilam
20213 citationsauthor #5
Filamin A inhibition reduces seizure activity in a mouse model of focal cortical malformations
202040 citationsauthor #7
PTI-125 Reduces Biomarkers of Alzheimer’s Disease in Patients
202035 citationsauthor #10
Abuse-deterrent properties of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
20181 citationsauthor #4
A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
20181 citationsauthor #4
Altered filamin A enables amyloid beta-induced tau hyperphosphorylation and neuroinflammation in Alzheimer’s disease
201725 citationsauthor #1
PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer's disease pathogenesis.
201737 citationsauthor #6
The clinical relevance of neuroplasticity in corticostriatal networks during operant learning.
201312 citationsauthor #4
Reducing Amyloid-Related Alzheimer's Disease Pathogenesis by a Small Molecule Targeting Filamin A
201258 citationsauthor #7
Ultra-Low-Dose Naloxone or Naltrexone to Improve Opioid Analgesia: The History, the Mystery and a Novel Approach
201025 citationsauthor #1
PTI-609: a novel analgesic that binds filamin A to control opioid signaling.
201024 citationsauthor #1
Ultra-Low-Dose Naltrexone Decreases Dependence and Addictive Properties of Opioids
20092 citationsauthor #1
Ultra-Low-Dose Opioid Antagonists Enhance Opioid Analgesia and Reduce Tolerance
20093 citationsauthor #1
Naloxone's Pentapeptide Binding Site on Filamin A Blocks Mu Opioid Receptor–Gs Coupling and CREB Activation of Acute Morphine
200966 citationsauthor #2
Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.
200873 citationsauthor #4
High-Affinity Naloxone Binding to Filamin A Prevents Mu Opioid Receptor–Gs Coupling Underlying Opioid Tolerance and Dependence
200884 citationsauthor #3
Survey of Medicare Part D Plans' Medication Therapy Management Programs
20075 citationsauthor #3
Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain.
2006140 citationsauthor #5
Gbetagamma that interacts with adenylyl cyclase in opioid tolerance originates from a Gs protein.
200623 citationsauthor #2
Gβγ that interacts with adenylyl cyclase in opioid tolerance originates from a Gs protein
200658 citationsauthor #2
Minimizes Physical Dependence While Providing ffective Analgesia : A Randomized Controlled Trial in Low ack Pain
20060 citationsauthor #5
Ultra-low-dose opioid antagonists enhance opioid analgesia while reducing tolerance , dependence and addictive properties
20057 citationsauthor #1
Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
200573 citationsauthor #4
Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex.
2005115 citationsauthor #5
Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats
200564 citationsauthor #2
Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor–G protein coupling and Gβγ signaling
2005168 citationsauthor #4
Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats.
200561 citationsauthor #2
Dissociation in Effects of Lesions of the Nucleus Accumbens Core and Shell on Appetitive Pavlovian Approach Behavior and the Potentiation of Conditioned Reinforcement and Locomotor Activity byd-Amphetamine
1999568 citationsauthor #3
Glutamate-dopamine interactions in the ventral striatum: role in locomotor activity and responding with conditioned reinforcement
199479 citationsauthor #1
Differential effects of excitotoxic lesions of the basolateral amygdala, ventral subiculum and medial prefrontal cortex on responding with conditioned reinforcement and locomotor activity potentiated by intra-accumbens infusions of D-amphetamine.
1993303 citationsauthor #1

TIMELINE

1993 303 citations

1994 79 citations

1999 568 citations

2005 488 citations

2006 221 citations

2007 5 citations

2008 157 citations

2009 71 citations

2010 49 citations

2012 58 citations

2013 12 citations

2017 62 citations

2018 2 citations

2020 75 citations

2021 6 citations

2023 36 citations

L. Burns

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT